The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| IART | -19.44% | -68.49% | -20.63% | +270% |
| S&P | +14.5% | +93.32% | +14.09% | +1,096% |
Integra LifeSciences Holdings Corp. engages in the provision of regenerative tissue technologies and neurological solutions dedicated to limiting uncertainty for clinicians. It operates under the Codman Specialty Surgical (CSS) and Tissue Technologies (TT) segments. The CSS segment includes technologies and instrumentation used for neurosurgery, neurocritical care, and otolaryngology. The TT segment focuses on complex wound surgery, surgical reconstruction, and peripheral nerve repair. The company was founded by Richard E. Caruso in 1989 and is headquartered in Princeton, NJ.
Q2 revenue and earnings beats didn't make up for the company's full-year guidance cut.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $415.61M | -0.6% |
| Gross Profit | $226.00M | -8.6% |
| Gross Margin | 54.38% | -4.7% |
| Market Cap | $953.53M | -58.5% |
| Market Cap / Employee | $0.22M | 0.0% |
| Employees | 4.4K | -17.5% |
| Net Income | -$484.07M | -3803.2% |
| EBITDA | $73.29M | 1.7% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $217.91M | 1.2% |
| Accounts Receivable | $284.51M | 2.4% |
| Inventory | 465.1 | 10.3% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $1.39B | -29.7% |
| Short Term Debt | $627.55M | 1516.1% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -12.93% | -13.5% |
| Return On Invested Capital | 3.36% | -0.4% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$11.23M | -205.0% |
| Operating Free Cash Flow | $8.92M | -77.9% |
| Metric | Q4 2023 | Q1 2024 | Q2 2024 | YoY Change | |
|---|---|---|---|---|---|
| Price to Earnings | 51.64 | 69.93 | 98.75 | - | |
| Price to Book | 0.92 | 1.15 | 1.10 | 0.63 | -56.44% |
| Price to Sales | 0.89 | 1.09 | 1.04 | 0.58 | -59.70% |
| Price to Tangible Book Value | -1.78 | -2.17 | -2.23 | -1.24 | -74.87% |
| Price to Free Cash Flow TTM | 45.23 | 38.30 | 36.52 | 70.11 | 50.21% |
| Enterprise Value to EBITDA | 62.08 | 34.44 | 48.06 | 36.86 | -33.10% |
| Free Cash Flow Yield | 2.2% | 2.6% | 2.7% | 1.4% | -33.43% |
| Return on Equity | -0.4% | -0.4% | -1.9% | -38.9% | -2747.30% |
| Total Debt | $1.99B | $1.98B | $2.02B | $2.01B | 0.21% |
IART earnings call for the period ending September 30, 2021.
IART earnings call for the period ending June 30, 2021.
IART earnings call for the period ending March 31, 2021.
IART earnings call for the period ending December 31, 2020.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
